drug

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigatio..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..

Eli Lilly to Cut 3,500 Jobs

Eli Lilly to Cut 3,500 Jobs

Drug making company Eli Lilly & Co. (NYSE:LLY)is planning on cutting 8.5% of their workforce and wants to close some facilities as the company is struggling with cost on some of their biggest products.The company has about 41,000 employees ..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..

Catalent Inc Shares Up After Strong Earnings

Catalent Inc Shares Up After Strong Earnings

Catalent Inc (NYSE: CTLT) shares jumped more than 13% Tuesday after the company announced fourth quarter and full year 2017 results. Catalent provides delivery technologies and development solutions for drugs, biologic, and consumer and animal healt..

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..

Valeant Pharmaceuticals Announced Q2 Earnings, Shares Jumped

Valeant Pharmaceuticals Announced Q2 Earnings, Shares Jumped

On Tuesday, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced its financial results for the second quarter. With earnings beating estimates, shares of the company increased 7.6% to $16.54 per share in morning trading on Tuesday after the announ..